MedTrace Logo

The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia

NCT00148447 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-05-03

No results posted yet for this study

Summary

The aim of this study is to evaluate the therapeutic effect of escitalopram in the treatment of negative symptoms in schizophrenia patients in a double-blind placebo-controlled study.

Conditions

Interventions

DRUG

escitalopram

Sponsors & Collaborators

  • Lundbeck Israel

    collaborator INDUSTRY

  • BeerYaakov Mental Health Center

    lead OTHER_GOV

Principal Investigators

  • Iulian Iancu, M.D. · Beer Yaakov Mental Health Center

  • Moshe Kotler, M.D. · Beer Yaakov Mental Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Completion
2005-09-30

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00148447 on ClinicalTrials.gov